Abstract
Foundation Medicine reported that effective February 6, Troy Cox would assume the position of chief executive officer to succeed Michael Pellini, M.D., who served as CEO since 2011. Dr. Pellini was appointed chairman of the company’s board of directors, while Alexis Borisy, founding CEO and previous chairman of the board, will continue to serve on the board of directors.
Dr. Pellini commented, “In the coming years, Foundation Medicine will face a series of key catalysts for company growth, and Troy’s strategic, commercial and organizational acumen will be particularly critical as we proceed through the FDA’s parallel review process and, if approved, prepare for the launch of the first FDA-approved universal companion diagnostic assay for cancer.”
Cox has nearly three decades of proven performance in global, strategic, and operational biopharma leadership. He joins Foundation Medicine from Roche-Genentech, where he oversaw an operation of more than 1,400 people while managing one of the largest oncology portfolios in the U.S.
Troy Cox, left, and Craig Venter, Ph.D., right.
